Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
Rare Disease Day is observed on the last day of February every year, and today – February 29th – is truly the rarest day.
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.
The Dynamics of Drug Shortages
9 January 2024
Drug shortages are an industry-wide problem. Numerous factors may be considered as contributing to drug shortages across the globe. In this report, we discuss the global issue of drug shortages, summarise the main reasons for shortages as presented in the literature and our quantitative analysis. Finally, we provide recommendations for policy makers.
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
This is part 2 of the insight series which explores how progress towards an effective pull incentive for antibiotics can be made in Europe.
Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
8 November 2023
NHS England conducted a public consultation on a ‘volume-delinked model’ subscription approach to address the market failure hindering the development of urgently needed antibiotics.
Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment
11 July 2023
This report contributes to the understanding of people’s proximity to dementia (e.g., people with dementia and their carers forecast) and so the potential future number of people who will be impacted by dementia, and the economic benefits arising from dementia research in the UK.
Investment in dementia research and medicine research and development (R&D) is significantly lower in comparison to other diseases such as cancer. However, recent breakthroughs and growing R&D pipeline show that this area has high potential for research over the next years. It is, therefore, important to estimate the benefits of dementia research to patients, their carers, the economy, and society.
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
The EU Commission has set out important but controversial proposals for an AMR pull incentive for new antibiotics. In the first of this insight series, we set out seven objectives an EU fit-for-purpose pull incentive should work to achieve.
New free educational program launched – Explaining the U.S. Inflation Reduction Act
9 May 2023
We have launched a free online explainer to the U.S. Inflation Reduction Act. It makes essential viewing for anyone wanting a sound knowledge of the technical detail of the Act and how it relates to pharmaceutical payment and coverage.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.